NAFLD, NASH and liver cancer

By G. Michelotti, M. Machado, A. Diehl. Nature Reviews Gastroenterology &Hepatology, 2013

966 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/c4c7ec46160f90aed7fa37c0ddcc889228b0f625

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Christopher D. Byrne
2. G. Targher
3. M. Karin

In Epidemiology

1. Christopher D. Byrne
2. G. Targher
3. M. Karin
4. Herbert Tilg

In Hepatology

1. Christopher D. Byrne
2. G. Targher
3. M. Karin

Citations in the corpus

• Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. (2014, background): “At the same time, there is no established pharmacological treatment for NASH, and therapy for HCC is limited (Michelotti et al., 2013).”
• NAFLD: a multisystem disease. (2015, background): “Activation of certain metabolic or stress-response pathways, involving one-carbon metabolism, nuclear factor-kappa B (NF-jB), phosphatase and tensin homolog (PTEN), and microRNAs occur with HCC [33].”